In the present study the clinicopathologic and immunophenotypic features of 82 patients with a CD30 ؊ peripheral T-cell lymphoma, unspecified, presenting in the skin were evaluated. The purpose of this study was to find out whether subdivision of these lymphomas on the basis of cell size, phenotype, or presentation with only skin lesions is clinically relevant. The study group included 46 primary cutaneous CD30 ؊ large cell lymphomas and 17 small/medium-sized T-cell lymphomas as well as 17 peripheral T-cell lymphomas with both skin and extracutaneous disease at the time of diagnosis. Patients with primary cutaneous small-or mediumsized T-cell lymphomas had a significantly better prognosis (5-year-overall survival, 45%) than patients with primary cutaneous CD30 ؊ large T-cell lymphomas (12%) and patients presenting with concurrent extracutaneous disease (12%). The favorable prognosis in this group with primary cutaneous small-or mediumsized T-cell lymphomas was particularly found in patients presenting with localized skin lesions expressing a CD3 ؉ CD4 ؉ CD8 ؊ phenotype. In the primary cutaneous T-cell lymphoma (CTCL) group and in the concurrent group, neither extent of skin lesions nor phenotype had any effect on survival. Our results indicate that peripheral T-cell lymphomas, unspecified, presenting in the skin have an unfavorable prognosis, irrespective of the presence or absence of extracutaneous disease at the time of diagnosis, cell size, and expression of a CD4 ؉ or CD8 ؉ phenotype. The only exception was a group of primary cutaneous small-or medium-sized pleomorphic CTCLs with a CD3 ؉ CD4 ؉ CD8 ؊ phenotype and presenting with localized skin lesions. (Blood.

No abstract

No abstract